Table 2 Demographic data and characteristics of the subjects in total, including those in the incidence study, and those who completed the incidence studya, b
From: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study
| Â | Total participants (N = 57) | Subjects included the study (N = 44) | Subjects completed the study (N = 35) |
|---|---|---|---|
Number of male patients | 24 (42.1) | 18 (40.9) | 13 (37.1) |
Age, years | 37.5 ± 12.7 | 35.5 ± 11.9 | 34.7 ± 11.2 |
Age at schizophrenia onset, years | 28.5 ± 11.9 | 26.8 ± 11.1 | 26.0 ± 10.3 |
Duration of antipsychotic treatment | 8.4 ± 6.3 | 8.2 ± 6.5 | 8.1 ± 6.3 |
Number of hospitalizations | 1.8 ± 2.2 | 1.8 ± 2.5 | 1.6 ± 2.3 |
Patients taking second-generation antipsychoticsc (including, clozapine, olanzapine, risperidone, and sertindole) | 33 (57.9) | 24 (54.5) | 19 (54.3) |
Patients reporting metabolic disturbances in their 1st degree relatives | Â | Â | Â |
   1. Obesity | 6 (10.5) | 5 (11.4) | 3 (8.6) |
   2. Dyslipidemia | 5 (8.8) | 4 (9.1) | 3 (8.6) |
   3. Hypertension | 20 (35.1) | 15 (34.1) | 13 (37.1) |
   4. Diabetes mellitus | 8 (14.0) | 6 (13.6) | 4 (11.4) |
Patients with cluster diseases of MetS | Â | Â | Â |
   1. Obesity (BMI ≥ 30 kg/m2) | 4 (7.0) | 2 (4.5) | 2 (5.7) |
   2. Central obesity (waist circumference ≥ 90 cm for men or ≥ 80 cm for women) | 27 (47.4) | 14 (31.8) | 11 (31.4) |
   3. High triglyceride level (≥ 150 mg/dL) | 22 (38.6) | 12 (27.3) | 10 (28.6) |
   4. Low HDL cholesterol level (<40 mg/dL for men or <50 mg/dL for women) | 16 (28.1) | 10 (22.7) | 8 (22.9) |
   5. High blood pressure (≥ 130/≥ 85 mm Hg) | 17 (29.8) | 11 (25.0) | 8 (22.9) |
   6. High fasting glucose level (≥ 100 mg/dL) | 16 (28.1) | 8 (18.2) | 6 (17.1) |